Fresita Proteins Q2 FY27: revenue Rs 81.03 lakh, PAT Rs 13.95 lakh
Standalone Q2 FY27 revenue from operations was Rs 81.03 lakh and PAT Rs 13.95 lakh, versus Rs 430.38 lakh and Rs 40.46 lakh a year earlier.
Q2 FY27 · standalone
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | Rs 81.03 lakh | Rs 430.38 lakh | -81.2% |
| PAT | Rs 13.95 lakh | Rs 40.46 lakh | -65.5% |
As reported in the filing. Figures are transcribed, not computed.
What the numbers show
- Net margin was 17.22% of revenue, up 781 bps from 9.40%.
- Revenue fell 81.2% while total expenses fell 84.5%.
- Purchases of stock-in-trade took 36.7% of revenue, against 89.9% a year earlier.
• Revenue from operations (quarter ended 30.09.2026): Rs 81.03 lakh, vs Rs 430.38 lakh in the quarter ended 30.09.2025 (statement of financial results, line I).
• Other income (quarter ended 30.09.2026): Rs - lakh, vs Rs 10.54 lakh in the quarter ended 30.09.2025 (line II).
• Total revenue – Total Revenue (I+II) (quarter ended 30.09.2026): Rs 81.03 lakh, vs Rs 440.92 lakh in the quarter ended 30.09.2025 (line III).
• Purchase of Stock-in-Trade (quarter ended 30.09.2026): Rs 29.73 lakh, vs Rs 387.12 lakh in the quarter ended 30.09.2025 (line ‘Purchase of Stock -in- Trade’).
• Employee Benefit Expenses (quarter ended 30.09.2026): Rs 12.75 lakh, vs Rs 0.75 lakh in the quarter ended 30.09.2025 (line ‘Employee Benefit Expenses’).
• Depreciation and Amortisation Expenses (quarter ended 30.09.2026): Rs - lakh, vs Rs - lakh in the quarter ended 30.09.2025 (line ‘Depreciation and Amoritsation Expenses’).
• Other expenses (quarter ended 30.09.2026): Rs 19.60 lakh, vs Rs 12.59 lakh in the quarter ended 30.09.2025 (line ‘Other expenses’).
• Total Expenses (quarter ended 30.09.2026): Rs 62.08 lakh, vs Rs 400.45 lakh in the quarter ended 30.09.2025 (line ‘Total Expenses (IV)’).
• Profit/(Loss) before tax (quarter ended 30.09.2026): Rs 18.95 lakh, vs Rs 40.46 lakh in the quarter ended 30.09.2025 (line ‘Profit/(Loss) before Tax (V-VI)’ / line IX).
• Profit/(Loss) for the period / PAT (quarter ended 30.09.2026): Rs 13.95 lakh, vs Rs 40.46 lakh in the quarter ended 30.09.2025 (line XV ‘Profit/(Loss) for the period (IX+XII)’).
• Total Comprehensive Income for the period (quarter ended 30.09.2026): Rs 13.95 lakh, vs Rs 40.46 lakh in the quarter ended 30.09.2025 (line XVII).
• Earnings per equity share – Basic (quarter ended 30.09.2026): 0.16, vs 2.34 in the quarter ended 30.09.2025 (line XVIII (1)).
• Earnings per equity share – Diluted (quarter ended 30.09.2026): 0.16, vs 2.34 in the quarter ended 30.09.2025 (line XVIII (2)).
For the quarter ended 30.09.2026, on a standalone basis, Fresita Proteins Limited reported revenue from operations of Rs 81.03 lakh and Total Revenue (I+II) of Rs 81.03 lakh, compared with Rs 430.38 lakh and Rs 440.92 lakh respectively in the corresponding quarter ended 30.09.2025, as per the statement of standalone unaudited financial results.
Total Expenses (IV) for the quarter ended 30.09.2026 were Rs 62.08 lakh, against Rs 400.45 lakh in the quarter ended 30.09.2025. Profit/(Loss) before Tax (V-VI) for the current quarter stood at Rs 18.95 lakh, compared with Rs 40.46 lakh in the same quarter of the previous year. Profit/(Loss) for the period (IX+XII) and Total Comprehensive Income for the period were both Rs 13.95 lakh for the quarter ended 30.09.2026, versus Rs 40.46 lakh a year earlier. Basic and Diluted earnings per equity share for the quarter were 0.16, compared with 2.34 in the corresponding quarter ended 30.09.2025.
Track Fresita Proteins Ltd
Cruxal reads every Fresita Proteins Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.
